
A
Untreated SW-620 / Main / E2
Dead 0.35%
Late 3.65%
Live 93.18%
Early 2.81%
B
SW-620 Treated with wtHALT-1 / Main / E2
Dead 11.82%
Late 14.36%
Live 70.44%
Early 3.38%
C
SW-620 Treated with mHALT-1 / Main / E2
Dead 0.64%
Late 13.46%
Live 69.98%
Early 15.92%
D
SW-620 Treated with Camptothecin / Main / E2
Dead 0.51%
Late 11.96%
Live 79.96%
Early 7.56%
E
Untreated SW-620 / Main / E2
Dead 2.21%
Late 8.11%
Live 81.46%
Early 8.22%
F
SW-620 Treated with wtHALT-1 / Main / E2
Dead 0.94%
Late 9.59%
Live 84.14%
Early 5.33%
G
SW-620 Treated with mHALT-1 / Main / E2
Dead 1.44%
Late 7.26%
Live 81.18%
Early 10.12%
H
SW-620 Treated with Camptothecin / Main / E2
Dead 0.77%
Late 16.63%
Live 63.86%
Early 18.74%
I
Untreated SW-620 / E2
Dead 0.07%
Late 1.90%
Live 88.70%
Early 9.32%
J
SW-620 Treated with wtHALT-1 / E2
Dead 0.09%
Late 2.46%
Live 93.37%
Early 4.08%
K
SW-620 Treated with mHALT-1 / E2
Dead 0.15%
Late 1.81%
Live 86.04%
Early 12.00%
L
SW-620 Treated with Camptothecin / E2
Dead 0.00%
Late 8.10%
Live 74.44%
Early 17.46%
PE-H
FITC-H